# Hims & Hers Q3 2026 Earnings Report

> Hims & Hers reports 49% revenue growth with international expansion accelerating.
- Title: Hims & Hers Q3 2026 Earnings Report · The Motley Fool
- Summary: Hims & Hers reports 49% revenue growth with international expansion accelerating.
- Keywords: hims, hers, q3 2026, revenue, subscribers, international expansion, weight loss, testosterone, peptides, ai native care, The Motley Fool
- Source: The Motley Fool — https://fool.com/earnings/call-transcripts/2026/11/10/hims-hers-hims-q3-2026-earnings-call-transcript
- Author: Motley Fool Transcribing
- Published: 2026-11-10T06:13:16+00:00
- Read time: 1 min
- Topics: hims, hers, q3 2026, revenue, subscribers, international expansion, weight loss, testosterone, peptides, ai native care, finance, money
## Q3 Revenue Growth
Revenue grew 49% year over year to $890.4 million.
## Subscribers
2.788 million subscribers, 13% year over year growth.
## International Expansion
Rest of world revenue grew 321% year over year following Eucalyptus acquisition.
## Adjusted EBITDA
Adjusted EBITDA of $82.4 million, 9% margin.
## Net Loss
Net loss of $33.0 million compared to net income of $15.8 million in prior year.
## Marketing Efficiency
Marketing efficiency improved 7 percentage points to 28% of revenue.
## Technology Investment
Technology and platform investment at 8% of revenue, largest engineering hiring quarter.
## Testosterone Offering
Testosterone specialty revenue approaching $100 million annualized run rate.
## Peptides+ Launch
Peptides+ offering launching late November 2026 with clinician-led treatment plans.
## Hers 2.0 App
Hers 2.0 app launched with integrated AI care coaching and expanded engagement tools.
## International Brands
Hers launched in Australia and Germany; Hims launched in Germany and Australia.
## AI Native Experience
AI native experience now available to large majority of weight loss customers.
## Weight Loss Partnerships
Agreement with Eli Lilly to expand access to Foundayo and Zepbound.
## Fourth Quarter Guidance
Q4 revenue guidance of $875 million to $895 million.
## Full Year 2026 Guidance
Full year 2026 revenue guidance of $3.13 billion to $3.15 billion.
## Subscribers Decline
Net subscriber decrease of 100,000 due to measured marketing spend.
## Key takeaway

Hims & Hers Health achieved $890.4 million Q3 revenue, 2.788 million subscribers, and a 9% adjusted EBITDA margin while expanding international markets.